Regulatory Roundup: FDA Publishes Final Guidance on Dissolution Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Publishes Final Guidance on Dissolution Testing

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA published as a final guidance Annex 7 to the ICH Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions guideline. As a second revision, Annex 7 focuses on dissolution testing. This annex is one of several pharmacopeial Q4B tests that has been harmonized by the ICH bodies in the US, Europe, and Japan in recent years. In terms of analytical procedures, the annex and FDA guidance say that the European Pharmacopeia 2.9.3. Dissolution Test for Solid Dosage Forms, the Japanese Pharmacopeia 6.10 Dissolution Test, and the US Pharmaceopeia <711> Dissolution, can be used interchangeably in the ICH regions. Some conditions apply according to the guidance. These include: the declaration of interchangeability applies to the Basket Apparatus, the Paddle Apparatus, and the Flow-Through Cell; the dissolution test is not considered to be interchangeable in the ICH regions when enzymes are used in the media; the dissolution apparatus should be appropriately calibrated to ensure compliance with regional GMPs; the test is not considered to be interchangeable in the three ICH regions for dosage forms referred to in the regional compendia as delayed-release, gastro-resistant, or enteric-coated; and finally, validation studies should be conducted to demonstrate that the test results are not adversely affected if the thermometer is to remain in the dissolution vessel per regional GMPs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here